



Stockholm, 2020-01-28

PRESS RELEASE

QuiaPEG Pharmaceuticals brings forward the date of publication of the year-end report

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG") has previously announced that the company's annual report for the period January-December 2019 will be published on March 6th, 2020. The Board of Directors of QuiaPEG has now decided to bring forward the date for publication of the interim report to February 28th, 2020.

For further information contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53

Email: marcus.bosson@quiapeg.com www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on January 28th, 2020, through the above contact person.

About QuiaPEG Pharmaceuticals

QuiaPEG Pharmaceuticals Holding AB conducts research and development and commercialization of pharmaceuticals based on the company's unique patent-pending technology platform, Uni-Qleaver[®]. The company develops improved and patentable forms of pharmaceuticals, which are under development or have already been approved by pharmaceutical authorities. These refined and improved forms of medicines are based on Uni-Qleaver[®]. The company's share has been listed on Spotlight Stock Market since March 29, 2017.